Tags

Type your tag names separated by a space and hit enter

Probiotics in the prevention of eczema: a randomised controlled trial.
Arch Dis Child. 2014 Nov; 99(11):1014-9.AD

Abstract

OBJECTIVE

To evaluate a multistrain, high-dose probiotic in the prevention of eczema.

DESIGN

A randomised, double-blind, placebo-controlled, parallel group trial.

SETTINGS

Antenatal clinics, research clinic, children at home.

PATIENTS

Pregnant women and their infants.

INTERVENTIONS

Women from 36 weeks gestation and their infants to age 6 months received daily either the probiotic (Lactobacillus salivarius CUL61, Lactobacillus paracasei CUL08, Bifidobacterium animalis subspecies lactis CUL34 and Bifidobacterium bifidum CUL20; total of 10(10) organisms/day) or matching placebo.

MAIN OUTCOME MEASURE

Diagnosed eczema at age 2 years. Infants were followed up by questionnaire. Clinical examination and skin prick tests to common allergens were done at 6 months and 2 years.

RESULTS

The cumulative frequency of diagnosed eczema at 2 years was similar in the probiotic (73/214, 34.1%) and placebo arms (72/222, 32.4%; OR 1.07, 95% CI 0.72 to 1.6). Among the secondary outcomes, the cumulative frequency of skin prick sensitivity at 2 years was reduced in the probiotic (18/171; 10.5%) compared with the placebo arm (32/173; 18.5%; OR 0.52, 95% CI 0.28 to 0.98). The statistically significant differences between the arms were mainly in sensitisation to cow's milk and hen's egg proteins at 6 months. Atopic eczema occurred in 9/171 (5.3%) children in the probiotic arm and 21/173 (12.1%) in the placebo arm (OR 0.40, 95% CI 0.18 to 0.91).

CONCLUSIONS

The study did not provide evidence that the probiotic either prevented eczema during the study or reduced its severity. However, the probiotic seemed to prevent atopic sensitisation to common food allergens and so reduce the incidence of atopic eczema in early childhood.

TRIAL REGISTRATION NUMBER

ISRCTN26287422.

Authors+Show Affiliations

College of Medicine, Swansea University, Swansea, UK.College of Human and Health Sciences, Swansea University, Swansea, UK.College of Medicine, Swansea University, Swansea, UK.College of Medicine, Swansea University, Swansea, UK.College of Medicine, Swansea University, Swansea, UK.Research and Development Department, Cultech Limited, Port Talbot, UK.Research and Development Department, Cultech Limited, Port Talbot, UK.Liverpool School of Tropical Medicine, Liverpool, L3 5QA, UK.College of Medicine, Swansea University, Swansea, UK.

Pub Type(s)

Journal Article
Randomized Controlled Trial
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

24947281

Citation

Allen, Stephen J., et al. "Probiotics in the Prevention of Eczema: a Randomised Controlled Trial." Archives of Disease in Childhood, vol. 99, no. 11, 2014, pp. 1014-9.
Allen SJ, Jordan S, Storey M, et al. Probiotics in the prevention of eczema: a randomised controlled trial. Arch Dis Child. 2014;99(11):1014-9.
Allen, S. J., Jordan, S., Storey, M., Thornton, C. A., Gravenor, M. B., Garaiova, I., Plummer, S. F., Wang, D., & Morgan, G. (2014). Probiotics in the prevention of eczema: a randomised controlled trial. Archives of Disease in Childhood, 99(11), 1014-9. https://doi.org/10.1136/archdischild-2013-305799
Allen SJ, et al. Probiotics in the Prevention of Eczema: a Randomised Controlled Trial. Arch Dis Child. 2014;99(11):1014-9. PubMed PMID: 24947281.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Probiotics in the prevention of eczema: a randomised controlled trial. AU - Allen,Stephen J, AU - Jordan,Sue, AU - Storey,Melanie, AU - Thornton,Catherine A, AU - Gravenor,Michael B, AU - Garaiova,Iveta, AU - Plummer,Susan F, AU - Wang,Duolao, AU - Morgan,Gareth, Y1 - 2014/06/19/ PY - 2014/6/21/entrez PY - 2014/6/21/pubmed PY - 2014/12/19/medline KW - Allergy KW - Dermatology KW - Microbiology SP - 1014 EP - 9 JF - Archives of disease in childhood JO - Arch. Dis. Child. VL - 99 IS - 11 N2 - OBJECTIVE: To evaluate a multistrain, high-dose probiotic in the prevention of eczema. DESIGN: A randomised, double-blind, placebo-controlled, parallel group trial. SETTINGS: Antenatal clinics, research clinic, children at home. PATIENTS: Pregnant women and their infants. INTERVENTIONS: Women from 36 weeks gestation and their infants to age 6 months received daily either the probiotic (Lactobacillus salivarius CUL61, Lactobacillus paracasei CUL08, Bifidobacterium animalis subspecies lactis CUL34 and Bifidobacterium bifidum CUL20; total of 10(10) organisms/day) or matching placebo. MAIN OUTCOME MEASURE: Diagnosed eczema at age 2 years. Infants were followed up by questionnaire. Clinical examination and skin prick tests to common allergens were done at 6 months and 2 years. RESULTS: The cumulative frequency of diagnosed eczema at 2 years was similar in the probiotic (73/214, 34.1%) and placebo arms (72/222, 32.4%; OR 1.07, 95% CI 0.72 to 1.6). Among the secondary outcomes, the cumulative frequency of skin prick sensitivity at 2 years was reduced in the probiotic (18/171; 10.5%) compared with the placebo arm (32/173; 18.5%; OR 0.52, 95% CI 0.28 to 0.98). The statistically significant differences between the arms were mainly in sensitisation to cow's milk and hen's egg proteins at 6 months. Atopic eczema occurred in 9/171 (5.3%) children in the probiotic arm and 21/173 (12.1%) in the placebo arm (OR 0.40, 95% CI 0.18 to 0.91). CONCLUSIONS: The study did not provide evidence that the probiotic either prevented eczema during the study or reduced its severity. However, the probiotic seemed to prevent atopic sensitisation to common food allergens and so reduce the incidence of atopic eczema in early childhood. TRIAL REGISTRATION NUMBER: ISRCTN26287422. SN - 1468-2044 UR - https://www.unboundmedicine.com/medline/citation/24947281/Probiotics_in_the_prevention_of_eczema:_a_randomised_controlled_trial_ L2 - http://adc.bmj.com/cgi/pmidlookup?view=long&pmid=24947281 DB - PRIME DP - Unbound Medicine ER -